Diagnosis and Treatment of ADHD in the Pediatric Population

Overview

Journal J Pediatr Pharmacol Ther

Specialty Pediatrics

Date 2024 Apr 10

PMID 38596418

Authors

Lea S Eiland

Brooke L Gildon

Affiliations

Soon will be listed here.

Abstract

Attention-deficit/hyperactivity disorder (ADHD) is one of the most common neurodevelopmental disorders in childhood with approximately 6 million children (age 3 to 17 years) ever diagnosed based on data from 2016-2019. ADHD is characterized by a constant pattern of inattention and/or hyperactivity-impulsivity symptoms that interferes with development or functioning. Specific criteria from the assist with the diagnosis with multiple guidelines available providing non-pharmacologic and pharmacologic recommendations for the treatment of ADHD in the pediatric population. While all guidelines similarly recommend behavioral and/or stimulant therapy as first-line therapy based on age, not all stimulant products are equal. Their differing pharmacokinetic profiles and formulations are essential to understand in order to optimize efficacy and safety for patients. Additionally, new stimulant products and non-stimulant medications continue to be approved for use of ADHD in the pediatric population and it is important to know their differences in formulation, efficacy, and safety to other products currently available. Lastly, due to drug shortages, it is important to understand product similarities and differences to select alternative therapy for patients.

References

Wolraich M, Hagan Jr J, Allan C, Chan E, Davison D, Earls M . Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Pediatrics. 2019; 144(4). PMC: 7067282. DOI: 10.1542/peds.2019-2528. View

Childress A, Brams M, Cutler A, Kollins S, Northcutt J, Padilla A . The Efficacy and Safety of Evekeo, Racemic Amphetamine Sulfate, for Treatment of Attention-Deficit/Hyperactivity Disorder Symptoms: A Multicenter, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled Crossover Laboratory Classroom Study. J Child Adolesc Psychopharmacol. 2015; 25(5):402-14. PMC: 4491157. DOI: 10.1089/cap.2014.0176. View

Penuelas-Calvo I, Jiang-Lin L, Girela-Serrano B, Delgado-Gomez D, Navarro-Jimenez R, Baca-Garcia E . Video games for the assessment and treatment of attention-deficit/hyperactivity disorder: a systematic review. Eur Child Adolesc Psychiatry. 2020; 31(1):5-20. DOI: 10.1007/s00787-020-01557-w. View

Harstad E, Levy S . Attention-deficit/hyperactivity disorder and substance abuse. Pediatrics. 2014; 134(1):e293-301. DOI: 10.1542/peds.2014-0992. View

Bitsko R, Claussen A, Lichstein J, Black L, Jones S, Danielson M . Mental Health Surveillance Among Children - United States, 2013-2019. MMWR Suppl. 2022; 71(2):1-42. PMC: 8890771. DOI: 10.15585/mmwr.su7102a1. View

Wigal S, Childress A, Belden H, Berry S . NWP06, an extended-release oral suspension of methylphenidate, improved attention-deficit/hyperactivity disorder symptoms compared with placebo in a laboratory classroom study. J Child Adolesc Psychopharmacol. 2013; 23(1):3-10. PMC: 3696913. DOI: 10.1089/cap.2012.0073. View

Wigal S, Childress A, Berry S, Belden H, Walters F, Chappell P . Efficacy and Safety of a Chewable Methylphenidate Extended-Release Tablet in Children with Attention-Deficit/Hyperactivity Disorder. J Child Adolesc Psychopharmacol. 2017; 27(8):690-699. PMC: 5651935. DOI: 10.1089/cap.2016.0177. View

Biederman J, Krishnan S, Zhang Y, McGough J, Findling R . Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther. 2007; 29(3):450-63. DOI: 10.1016/s0149-2918(07)80083-x. View

Deang K, Sidi H, Zakaria H, Adam R, Das S, Hatta N . The Novelty of Bupropion As a Dopaminergic Antidepressant for the Treatment of Adult Attention Deficit Hyperactive Disorder. Curr Drug Targets. 2017; 20(2):210-219. DOI: 10.2174/1389450118666170511145628. View

10.

Cortese S . Pharmacologic Treatment of Attention Deficit-Hyperactivity Disorder. N Engl J Med. 2020; 383(11):1050-1056. DOI: 10.1056/NEJMra1917069. View

11.

Danielson M, Holbrook J, Bitsko R, Newsome K, Charania S, McCord R . State-Level Estimates of the Prevalence of Parent-Reported ADHD Diagnosis and Treatment Among U.S. Children and Adolescents, 2016 to 2019. J Atten Disord. 2022; 26(13):1685-1697. PMC: 9489617. DOI: 10.1177/10870547221099961. View

12.

Oh S, Choi J, Han D, Kim E . Effects of game-based digital therapeutics on attention deficit hyperactivity disorder in children and adolescents as assessed by parents or teachers: a systematic review and meta-analysis. Eur Child Adolesc Psychiatry. 2023; 33(2):481-493. DOI: 10.1007/s00787-023-02174-z. View

13.

Briars L, Todd T . A Review of Pharmacological Management of Attention-Deficit/Hyperactivity Disorder. J Pediatr Pharmacol Ther. 2016; 21(3):192-206. PMC: 4956327. DOI: 10.5863/1551-6776-21.3.192. View

14.

Barbaresi W, Campbell L, Diekroger E, Froehlich T, Liu Y, OMalley E . Society for Developmental and Behavioral Pediatrics Clinical Practice Guideline for the Assessment and Treatment of Children and Adolescents with Complex Attention-Deficit/Hyperactivity Disorder. J Dev Behav Pediatr. 2020; 41 Suppl 2S:S35-S57. DOI: 10.1097/DBP.0000000000000770. View

15.

Young S, Abbasian C, Al-Attar Z, Branney P, Colley B, Cortese S . Identification and treatment of individuals with attention-deficit/hyperactivity disorder and substance use disorder: An expert consensus statement. World J Psychiatry. 2023; 13(3):84-112. PMC: 10075023. DOI: 10.5498/wjp.v13.i3.84. View

16.

. Drugs for ADHD. Med Lett Drugs Ther. 2020; 62(1590):9-15. View

17.

Wolraich M, Chan E, Froehlich T, Lynch R, Bax A, Redwine S . ADHD Diagnosis and Treatment Guidelines: A Historical Perspective. Pediatrics. 2019; 144(4). DOI: 10.1542/peds.2019-1682. View

18.

Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes A, Carucci S . Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018; 5(9):727-738. PMC: 6109107. DOI: 10.1016/S2215-0366(18)30269-4. View

19.

Pliszka S . Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007; 46(7):894-921. DOI: 10.1097/chi.0b013e318054e724. View

20.

Yamaguchi I, Hanevold C . Evaluation and Management of Elevated Blood Pressure in Children and Adolescents with Attention Deficit Hyperactivity Disorder. Curr Hypertens Rep. 2019; 21(8):60. DOI: 10.1007/s11906-019-0968-1. View